Lauxera Capital Partners has invested €50 million in neurovascular medical device company Acandis—a transaction that marks the firm’s first investment out of Lauxera Growth II, its second-generation healthcare growth buyout fund.
Key uses of funds from this transaction include accelerating commercialisation activities in direct markets and executing US clinical trials to achieve US market access for key Acandis products. The company will also explore external growth opportunities to broaden its reach and deepen its portfolio, as per a press release.
Acandis co-founders, Andreas and Kirsi Schuessler, commented: “After interacting with numerous investment firms, we decided to partner with Lauxera because of their deep experience developing and commercialising medical devices, their humility, ‘can-do’ attitude, and strong links to the US market. It felt like a true partnership from the first day Lauxera started due diligence, and we are excited to build our family business alongside Sam, Edoardo and the broader Lauxera team.”
“What Kirsi and Andreas have accomplished at Acandis over the past 19 years is a remarkable medical device entrepreneurial success story,” added Samuel Levy, founding partner at Lauxera. “They have brought numerous classes of innovative medical devices to market, both saving lives and delighting physician customers. Our goal is to help Kirsi and Andreas successfully lead the next chapter of the company’s extraordinary growth journey.”
The recent release notes that, with state-of-the-art manufacturing facilities and commercial operations in more than 60 countries, Acandis is fully vertically integrated and rapidly growing. Since its inception, the Germany-based firm has demonstrated an aptitude for continuous innovation, establishing itself as a pioneer in the flow diverter, rescue stenting, mechanical thrombectomy and biologically active device coating fields, the release continues.
The company has launched 17 product families with an emphasis on improving patient outcomes and procedure ease. In addition to highlighting its “excellence in stent design”, the release notes that Acandis has boasted a compound annual growth rate (CAGR) exceeding 25% since 2021 and is therefore well-positioned to outpace the fast-growing global neurovascular medical device market.
Acandis is the inaugural investment recipient of Lauxera Growth II—a growth buyout successor fund that commenced fundraising in Q3 2024. With its first close in December 2024, the vehicle has already “substantially surpassed” the size of its predecessor vehicle, Lauxera Growth I, a €262 million fund. That is according to Lauxera’s recent press release.
“Acandis’ ability to combine robust, consistent growth, manufacturing excellence, and superior research and innovation—while maintaining flexibility and agility—truly reflects the founders’ motto: ‘We always give every good idea a chance’,” stated Edoardo Fracchia, partner at Lauxera.
